UNH Stock: Buy or Sell? Price Target & Forecast

UNH UnitedHealth Group Inc As of Jul 30, 2026

$420.57

Healthcare giant with stretched valuation, mixed momentum, and insider accumulation signaling conviction.

Setup: Quality growth at premium; recovery play on margin pressure. Confidence: 62 Horizon: 6-12 months Risk: medium Category: Large-Cap Healthcare

🔒 Trade Plan — entry · target · stop

Entry Zone

$•••–•••

Target

$•••

Stop Loss

$•••

Risk / Reward

•.• : 1

Unlock the exact levels — free →

A free account reveals UNH's entry zone, price target & stop loss. Full 1-week to 1-year price forecasts are included with Pro.

The Thesis

▲ Bull Case

Dominant market position in managed care & healthcare services; 11.35% revenue growth; insiders heavily accumulating (4.5:1 buy-to-sell ratio); 2.2% dividend yield; cost-control narrative gaining traction post-earnings season; secular tailwind from aging population & healthcare utilization.

▼ Bear Case

Forward P/E 32x is stretched for only 2.7% net margin and -14.5% YoY EPS decline; current ratio 0.89 shows tight liquidity; net margin compression from regulatory/cost pressures; near 9% YTD drawdown signals technical weakness; payout ratio 65.7% limits reinvestment flexibility.

Valuation

Overvalued on near-term metrics; fair on long-term growth. — score 48/100

Forward P/E 32x is elevated for a company with -14.5% YoY EPS decline and 2.7% net margin. P/S 0.87 and EV/EBITDA 18.7x are reasonable for its scale, but multiple expansion doesn't justify the premium given margin compression. P/B 3.18 and price-to-FCF 24.6x suggest investors are pricing in a recovery that hasn't materialized yet.

Technical Levels

Support · $400.00 (Psychological/recent entry zone) · $390.00 (Stop-loss level; 200-day MA support (estimated)) · $375.00 (2024 intermediate support)

Resistance · $431.68 (Day high; near-term resistance) · $450.00 (Key supply zone) · $461.62 (52-week high; all-time resistance)

Financial Health

Score 58/100. Balance sheet shows adequate equity backing (book value $103.87/share, tangible $81.28/share) and strong net assets for the sector. However, liquidity is tight: current ratio 0.89 means current liabilities exceed current assets by ~11%, and quick ratio 0.67 is well below the 1.0 comfort level. This is not unusual for large healthcare insurers with predictable, steady cash flows, but limits financial flexibility for M&A, special dividends, or downturns. Payout ratio 65.7% is sustainable but elevated. Debt-to-equity unavailable; unable to assess leverage risk.

Catalysts

Q3 2024 Earnings & Guidance	Late October 2024 (estimated)	High. Market will reassess cost-control progress, medical cost trends, and FY2025 guidance. A beat + raised guidance could reignite multiple expansion; miss could trigger sell-off toward $380–$390.
Change Healthcare Integration Updates	Ongoing through 2024–2025	Medium. Successfully integrating Change Healthcare (acquired 2022) and realizing synergies would validate management credibility and drive margin expansion narrative.
Dividend Increase Announcement	Typically Q4 or early 2025	Low-Medium. 2.2% yield is modest; a hike to 2.4–2.5% would signal management confidence and attract income investors. However, tight liquidity may constrain size.
Medicare Advantage Rate Decisions & CMS Policy	Ongoing; major announcements in spring/fall	High. Rate cuts or tighter prior authorization rules reduce insurer margins. Stability signals would support the bull case.

Risk Flags

Forward P/E 32x vs. trailing 27.4x suggests earnings deceleration; monitor Q3/Q4 guidance closely.

Current ratio 0.89 and quick ratio 0.67 indicate tight working capital; any dividend hike or M&A would stress balance sheet.

EPS growth -14.5% YoY is significant headwind; recovery depends on medical cost control narrative holding.

Stock -1.9% today and -9% YTD; breakout from 52-week range ($234.60–$461.62) requires sustained earnings stabilization.

Provider data lacks ROE, ROA, ROIC, debt-to-equity, interest coverage — unable to fully assess capital efficiency and debt burden.

See UNH's full trade plan — free

Create a free account to unlock the exact entry, target, and stop — plus run live analysis on any of 5,000+ tickers. No card required.

Unlock UNH free →

More Analyses

NVDA

AAPL

TSLA

MSFT

AMZN

GOOGL

UNH FAQ

Is UNH a buy right now?

UnitedHealth Group Inc's current read is a Quality growth at premium; recovery play on margin pressure. setup with 62 confidence over a 6-12 months horizon. Valuation: Overvalued on near-term metrics; fair on long-term growth.. See the full bull and bear case above, or run a live analysis for the exact entry, target and stop.

Is UNH overvalued?

Overvalued on near-term metrics; fair on long-term growth. (valuation score 48/100). Forward P/E 32x is elevated for a company with -14.5% YoY EPS decline and 2.7% net margin. P/S 0.87 and EV/EBITDA 18.7x are reasonable for its scale, but multiple expansion doesn't justify the premium given margin compression. P/B 3.18 and price-to-FCF 24.6x suggest investors are pricing in a recovery that hasn't materialized yet.

What are the risks of buying UNH?